540 related articles for article (PubMed ID: 19264554)
1. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
Gamé X; Mouracade P; Chartier-Kastler E; Viehweger E; Moog R; Amarenco G; Denys P; De Seze M; Haab F; Karsenty G; Kerdraon J; Perrouin-Verbe B; Ruffion A; Soler JM; Saussine C
J Pediatr Urol; 2009 Jun; 5(3):156-64. PubMed ID: 19264554
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
[TBL] [Abstract][Full Text] [Related]
3. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
[TBL] [Abstract][Full Text] [Related]
4. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity.
Hui C; Keji X; Chonghe J; Ping T; Rubiao O; Jianweng Z; Xiangrong D; Liling Z; Maping H; Qingqing L; Qiuling L; Jiebing H; Tanghai H
Spinal Cord; 2016 Jan; 54(1):46-50. PubMed ID: 26261074
[TBL] [Abstract][Full Text] [Related]
5. Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity.
Gomes CM; Castro Filho JE; Rejowski RF; Trigo-Rocha FE; Bruschini H; Barros Filho TE; Srougi M
Int Braz J Urol; 2010; 36(1):66-74. PubMed ID: 20202238
[TBL] [Abstract][Full Text] [Related]
6. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X
Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
9. Botulinum injection is useless on fibrotic neuropathic bladders.
Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
[TBL] [Abstract][Full Text] [Related]
10. Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity-A systematic review and meta-analysis.
Ni J; Wang X; Cao N; Si J; Gu B
Neurourol Urodyn; 2018 Feb; 37(2):542-553. PubMed ID: 28745818
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
[TBL] [Abstract][Full Text] [Related]
12. How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity.
Mailho C; Peyronnet B; De Seze M; Even A; Perrouin-Verbe MA; Amarenco G; Chartier-Kastler E; Le Normand L; Manunta A; Karsenty G; Kerdraon J; Ruffion A; Saussine C; Le Breton F; Bernuz B; Castel-Lacanal E; Denys P; Phé V; Gamé X
Neurourol Urodyn; 2024 Apr; 43(4):811-817. PubMed ID: 38451038
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review.
Soljanik I
Drugs; 2013 Jul; 73(10):1055-66. PubMed ID: 23775527
[TBL] [Abstract][Full Text] [Related]
15. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.
Linsenmeyer TA
J Spinal Cord Med; 2013 Sep; 36(5):402-19. PubMed ID: 23941788
[TBL] [Abstract][Full Text] [Related]
16. Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity.
Avallone MA; Sack BS; El-Arabi A; Guralnick ML; O'Connor RC
Neurourol Urodyn; 2017 Apr; 36(4):1104-1107. PubMed ID: 27283922
[TBL] [Abstract][Full Text] [Related]
17. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
[TBL] [Abstract][Full Text] [Related]
18. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
Ellsworth P; Travis M
Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of trigonal BTX-A injections for children with neurological detrusor overactivity secondary to spinal cord injury.
Hui C
J Pediatr Surg; 2020 Dec; 55(12):2736-2739. PubMed ID: 32571538
[TBL] [Abstract][Full Text] [Related]
20. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.
Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P
J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
